Linagliptin Sandoz

Linagliptin, the active ingredient in Linagliptin Sandoz, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as a tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults.

GNH USA supplies Linagliptin Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is a DPP‑4 inhibitor used in the treatment of type 2 diabetes mellitus. It helps lower blood glucose when combined with diet and exercise.

- Type 2 diabetes mellitus: improves glycemic control as part of a comprehensive treatment plan. - Adjunct to metformin: provides additional HbA1c reduction when metformin alone is insufficient. - Combination therapy: can be co‑administered with insulin or other oral agents to achieve target glucose levels.

Linagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nasal passages and throat. - Headache: transient, mild to moderate intensity. - Upper respiratory tract infection: symptoms of cough, sore throat, or congestion. - Dizziness: occasional light‑headedness, especially on standing. - Gastrointestinal discomfort: mild nausea or abdominal pain.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with vomiting, requiring immediate medical attention. - Severe allergic reactions: anaphylaxis, angioedema, or rash requiring discontinuation. - Hepatic injury: elevated liver enzymes or hepatitis signs. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating Linagliptin, clinicians should consider several safety factors.

- Renal impairment: dose adjustment is generally not required, but renal function should be monitored. - Hepatic impairment: use with caution in patients with moderate to severe liver disease. - Cardiovascular disease: no specific contraindication, but monitor for any new symptoms. - Hypoglycemia risk: increased when combined with insulin or sulfonylureas; adjust concomitant therapy accordingly. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Store at room temperature: keep in the original container, protect from moisture and light.

Linagliptin may interact with other medicines, requiring attention to dosing and monitoring.

Major Interactions (Avoid): - Insulin or sulfonylureas: may cause severe hypoglycemia; dose adjustments are necessary. - Strong CYP3A4 inhibitors (e.g., ketoconazole): can increase linagliptin exposure and risk of adverse effects. - Rifampin: may reduce linagliptin efficacy by inducing metabolism.

Moderate Interactions (Monitor Closely):\n- Diuretics: monitor for dehydration, especially in elderly patients. - ACE inhibitors: observe blood pressure and renal function. - Warfarin: periodic INR monitoring is advised due to potential interaction.